British Journal of Haematology · 2005 · 110 citations · 13 references
MedicineHematologyImmunologyChemotherapyStem Cell TransplantationTransplant ImmunologyEngraftment MonitoringHematopoietic Stem Cell Transplant PharmacotherapyImmunosuppressionImmunosuppression ManagementImmunosuppressive TherapyAnti-thymocyte Globulin ConditioningAplastic Anemia TransplantationCyclophosphamide-based ConditioningImmunosuppressive Drug TherapyPost-transplant CyclophosphamideSurvival After Allogeneic TransplantationTransplantation For Hematologic MalignanciesTransplantation Outcome Assessment
A total of 81 severe aplastic anaemia patients, aged 2-63 years, received human leucocyte antigen-matched related marrow grafts after cyclophosphamide + antithymocyte globulin followed by postgrafting methotrexate + cyclosporin. Median follow-up was 9.2 years. Ninety-six per cent of patients had sustained engraftment, 24% developed acute graft-versus-host disease (GVHD), grade II in all but two patients, and 26% developed chronic GVHD; all surviving patients eventually responded to immunosuppressive therapy. Six patients developed cancer: one fatal lymphoma and five carcinomas (all five patients are now free of cancer). Survival was 88%. The regimen appeared well tolerated and effective in heavily pretreated patients with aplastic anaemia.
13
Malignant Tumors Occurring after Treatment of Aplastic Anemia
Gèrard Socié, M. Henry‐Amar, Andrea Bacigalupo et al. · New England Journal of Medicine · 1993 · 466 citations · Full text
Medicine, Hematology, Oncology +16